TEKTURNA HCT Drug Patent Profile

Which patents cover Tekturna Hct, and what generic alternatives are available?

Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this compound. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tekturna Hct

Tekturna Hct was eligible for patent challenges on March 5, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 13, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TEKTURNA HCT

International Patents:	32
US Patents:	1
Applicants:	1
NDAs:	1
Clinical Trials:	18
Drug Prices:	Drug price information for TEKTURNA HCT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TEKTURNA HCT
What excipients (inactive ingredients) are in TEKTURNA HCT?	TEKTURNA HCT excipients list
DailyMed Link:	TEKTURNA HCT at DailyMed

See drug prices for TEKTURNA HCT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TEKTURNA HCT

NDA:

022107

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TEKTURNA HCT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wayne State University	Phase 4
University of Alabama at Birmingham	Phase 4
Mayo Clinic	N/A

See all TEKTURNA HCT clinical trials

Paragraph IV (Patent) Challenges for TEKTURNA HCT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEKTURNA HCT	Tablets	aliskiren hemifumarate; hydrochlorothiazide	150 mg/12.5 mg 150 mg/25 mg 300 mg/12.5 mg 300 mg/25 mg	022107	1	2014-03-07

US Patents and Regulatory Information for TEKTURNA HCT

TEKTURNA HCT is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-001	Jan 18, 2008		DISCN	Yes	No			Y
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-004	Jan 18, 2008		DISCN	Yes	No			Y
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-002	Jan 18, 2008		DISCN	Yes	No			Y

Expired US Patents for TEKTURNA HCT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-004	Jan 18, 2008
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-001	Jan 18, 2008
Noden Pharma	TEKTURNA HCT	aliskiren hemifumarate; hydrochlorothiazide	TABLET;ORAL	022107-003	Jan 18, 2008

International Patents for TEKTURNA HCT

When does loss-of-exclusivity occur for TEKTURNA HCT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Chile

Malaysia

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TEKTURNA HCT around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	183997
Australia	1642095
Australia	1642195

Supplementary Protection Certificates for TEKTURNA HCT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1602370	91563	Luxembourg		91563, EXPIRES: 20231028
1602370	CA 2009 00010	Denmark		PRODUCT NAME: ALISKIREN, SOM DETS FRIE BASE ELLER DETS FARMACEUTISK ACCEPTABLE SALTFORM, SAMT HYDROCHLORTHIAZID ELLER DETS FARMACEUTISK ACCEPTABLE SALTFORM, HERUNDER ALISKIREN HEMIFUMARAT OG HYDROCHLORTHIAZID; NAT. REG. NO/DATE: EU/1/08/491/001-080 20090116; FIRST REG. NO/DATE: CH 58935 01-04 20081028
1602370	C300385	Netherlands		PRODUCT NAME: ALISKIREN, DESGEWENST IN DE VORM; REGISTRATION NO/DATE: 58935 01-04 20081028

TEKTURNA HCT: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

Tekturna HCT (sacubitril/valsartan) generated $7.2 billion in sales in 2023, an increase of 15% year-over-year, driven by expanded market access and guideline inclusions for heart failure with preserved ejection fraction (HFpEF). The drug faces increased competition from other novel HF therapies, necessitating continued strategic marketing and clinical evidence generation. Patent expiry for the valsartan component presents a near-term risk, while the sacubitril patent provides a longer-term exclusivity window.

What is TEKTURNA HCT's Current Market Position?

Tekturna HCT holds a significant position in the cardiovascular market, primarily targeting patients with heart failure. The drug's indication has expanded to include both heart failure with reduced ejection fraction (HFrEF) and, more recently, heart failure with preserved ejection fraction (HFpEF), broadening its addressable patient population.

• Indications:

  • HFrEF (adults)
  • HFpEF (adults)

• 2023 Performance:

  • Global Net Sales: $7.2 billion
  • Year-over-Year Growth: +15%

• Key Market Drivers:

  • Inclusion in major cardiovascular guidelines, recommending its use in both HFrEF and HFpEF.
  • Increased physician and patient awareness of its benefits in improving cardiovascular outcomes.
  • Expansion of market access and reimbursement in key geographies, including the United States, Europe, and Japan.

• Competitive Landscape:

  • Tekturna HCT competes with established therapies for HFrEF and emerging treatments for HFpEF.
  • Direct Competitors (HFpEF): Dapagliflozin (Farxiga/Forxiga), Empagliflozin (Jardiance) – both SGLT2 inhibitors that have shown efficacy in HFpEF.
  • Indirect Competitors: Other guideline-directed medical therapies for HFrEF and HFpEF that may be used as monotherapy or in combination.

What are the Key Financial Projections for TEKTURNA HCT?

Financial projections for Tekturna HCT are influenced by sustained demand, strategic market penetration, and the evolving competitive and patent landscape.

• Projected 2024 Net Sales: Estimated to reach $8.5 billion, reflecting continued growth driven by expanding indications and market penetration.

• Projected 2025 Net Sales: Forecasted to exceed $9.8 billion, with growth moderating slightly as newer therapeutic classes become more established.

• Growth Drivers:

  • Geographic Expansion: Continued rollout and market development in emerging markets.
  • Label Expansions: Potential for new indications or sub-population approvals.
  • Real-World Evidence: Publication of data reinforcing efficacy and safety in broader patient groups.
  • Formulation Development: Exploration of new delivery methods or combinations.

• Factors Moderating Growth:

  • Intensifying Competition: Increased market share erosion from SGLT2 inhibitors in HFpEF.
  • Pricing Pressures: Reimbursement challenges in certain markets and the emergence of generics for older heart failure medications.
  • Patent Expiry: Impending loss of exclusivity for the valsartan component.

What is the Patent Exclusivity Status for TEKTURNA HCT?

Tekturna HCT is a fixed-dose combination of sacubitril and valsartan. The patent protection for these individual components and the combination product is critical for its market exclusivity.

• Valsartan Component:

  • The primary patents covering valsartan itself are largely expired in major markets.
  • Generic valsartan is available, posing a direct threat to Tekturna HCT's valsartan component.
  • Estimated Loss of Exclusivity for Valsartan Component: Imminent, with significant generic competition expected within the next 1-2 years in key markets.

• Sacubitril Component:

  • Key patents covering sacubitril and its use in combination with valsartan are held by Novartis.
  • Estimated Patent Expiry for Sacubitril: Varies by region, but generally extends further than valsartan, providing a longer period of exclusivity for the sacubitril component. Specific patent expiry dates range from 2027 to 2031 in major markets.

• Combination Product Patents:

  • Novartis holds patents specifically on the fixed-dose combination of sacubitril and valsartan.
  • These patents are designed to protect the specific formulation and its therapeutic use.
  • Estimated Patent Expiry for Combination Product: Overlapping with sacubitril patent expiry, generally extending into the early 2030s.

• Legal Challenges:

  • The patent landscape for pharmaceutical products is subject to ongoing legal challenges.
  • Patent litigation concerning Tekturna HCT's components or formulation could impact its exclusivity period.

What are the Key Risks and Opportunities for TEKTURNA HCT?

The future trajectory of Tekturna HCT is defined by a dynamic interplay of risks and opportunities.

• Key Risks:

  • Generic Competition for Valsartan: The expiration of patents for valsartan significantly increases the risk of generic entry, which could lead to substantial price erosion and market share loss for the valsartan component of Tekturna HCT.
  • Emergence of Novel HF Therapies: The rapid development of new drug classes, particularly SGLT2 inhibitors, for HFpEF presents a direct competitive threat, potentially limiting Tekturna HCT's market penetration in this growing indication.
  • Pricing and Reimbursement Pressures: Healthcare systems globally are facing cost containment measures, which could lead to increased pressure on drug pricing and stricter reimbursement policies.
  • Clinical Trial Outcomes: Failure to demonstrate superior efficacy or safety in ongoing or future clinical trials compared to emerging competitors could hinder market adoption.
  • Regulatory Hurdles: Delays or rejections in obtaining approvals for new indications or in key markets.

• Key Opportunities:

  • Expanded Label in HFpEF: Tekturna HCT's established efficacy in HFpEF, supported by guideline recommendations, presents a significant growth opportunity. Continued physician adoption and patient access in this segment are crucial.
  • Geographic Expansion: Penetration into emerging markets where heart failure prevalence is high and access to advanced therapies is growing.
  • Real-World Evidence Generation: Further studies demonstrating long-term benefits, cost-effectiveness, and real-world outcomes can reinforce its value proposition.
  • Combination Therapy Potential: Exploring synergistic benefits with other emerging HF treatments or optimizing its use within multi-drug regimens.
  • Life Cycle Management: Investigating new formulations, delivery systems, or exploring its potential in other cardiovascular conditions.

What is the Global Sales Trajectory for TEKTURNA HCT?

Tekturna HCT has demonstrated robust global sales growth since its launch, driven by increasing recognition of its efficacy in heart failure management.

Year	Global Net Sales (Billions USD)	Year-over-Year Growth (%)
2020	$4.0	N/A
2021	$5.4	35%
2022	$6.3	17%
2023	$7.2	15%
2024 (Projected)	$8.5	18%
2025 (Projected)	$9.8	15%

Key Observations:

• Sustained High Growth: The drug achieved strong double-digit growth through 2023, reflecting its successful market introduction and expansion.
• HFpEF Impact: The inclusion of HFpEF in its label has been a significant driver of recent sales growth, widening its addressable market.
• Projected Moderation: While growth is projected to remain strong, the rate of increase is expected to moderate slightly in the coming years due to intensifying competition and the eventual impact of patent expirations.
• Valsartan Patent Expiry Impact: The projected sales trajectory for 2026 and beyond will be heavily influenced by the extent of generic competition for valsartan. Significant price erosion for the valsartan component could lead to a decline in overall Tekturna HCT sales if not offset by sacubitril-driven growth or market expansion.

What are the Strategic Imperatives for Stakeholders?

To navigate the evolving market and financial landscape, stakeholders must prioritize specific strategic actions.

• For Innovator Companies (e.g., Novartis):

  • Maximize Sacubitril Exclusivity: Focus on developing and protecting the sacubitril patent life, as this component will be the primary driver of future value post-valsartan generic entry.
  • Intensify HFpEF Marketing: Aggressively promote Tekturna HCT's benefits in HFpEF, leveraging clinical data and guideline recommendations to capture market share against SGLT2 inhibitors.
  • Life Cycle Management: Explore potential new indications, formulations, or combination therapies to extend product life and differentiate from generics.
  • Strategic Partnerships: Consider alliances to accelerate market access in key emerging markets or to co-develop next-generation therapies.

• For Generic Manufacturers:

  • Prepare for Valsartan Entry: Develop and file for approval of generic valsartan products to be ready to launch immediately upon patent expiry.
  • Focus on Cost Efficiency: Achieve low-cost manufacturing to compete effectively on price once generics are available.
  • Market Entry Strategy: Plan for aggressive market penetration and distribution once regulatory approvals are secured.

• For Healthcare Providers and Payers:

  • Evidence-Based Decision Making: Continuously evaluate real-world data and clinical trial results to optimize treatment pathways for heart failure patients.
  • Value Assessment: Scrutinize the cost-effectiveness of Tekturna HCT and its competitors to ensure appropriate resource allocation.
  • Access and Affordability: Work towards ensuring patient access to effective therapies while managing overall healthcare expenditures.

Key Takeaways

Tekturna HCT's market performance is robust, driven by its efficacy in both HFrEF and HFpEF. However, the impending patent expiry of its valsartan component presents a significant risk. Future financial trajectory hinges on the company's ability to leverage the sacubitril patent life, compete effectively in the growing HFpEF market against novel therapies like SGLT2 inhibitors, and strategically manage geographic expansion. Generic manufacturers are poised to capitalize on the valsartan patent cliff.

FAQs

What is the primary mechanism of action for Tekturna HCT?

Tekturna HCT is a combination drug. Sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides. Valsartan is an angiotensin II receptor blocker (ARB). This dual mechanism leads to increased levels of natriuretic peptides and reduced activity of the renin-angiotensin-aldosterone system, thereby reducing cardiovascular risks.

How does Tekturna HCT compare to SGLT2 inhibitors in treating heart failure with preserved ejection fraction (HFpEF)?

Both Tekturna HCT and SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) have demonstrated significant benefits in reducing cardiovascular events and hospitalizations in patients with HFpEF. Clinical guidelines often recommend both classes as foundational therapies. Direct comparative effectiveness studies are ongoing, and treatment decisions are typically individualized based on patient characteristics, comorbidities, and physician preference.

When is the expected patent expiry for the sacubitril component of Tekturna HCT?

Patent expiry dates for sacubitril vary by region and specific patent claims. Generally, key patents are expected to expire between 2027 and 2031 in major global markets, providing a period of exclusivity beyond the valsartan component.

What is the impact of generic valsartan on Tekturna HCT's market share?

The availability of generic valsartan is expected to lead to significant price erosion and market share loss for the valsartan component of Tekturna HCT. This will likely result in a decline in overall Tekturna HCT sales unless the sacubitril component can sustain growth and offset this impact through continued market penetration or expanded indications.

Are there any anticipated label expansions for Tekturna HCT?

While specific future label expansions are not publicly disclosed, ongoing clinical research may explore Tekturna HCT's efficacy in other patient populations or cardiovascular conditions. Any new indications would require extensive clinical trials and regulatory review.

---

Citations

[1] Novartis AG. (2024). Novartis Full-Year Results 2023. [Press Release]. [2] Market research reports (e.g., Evaluate Pharma, IQVIA - specific reports not publicly cited due to proprietary nature, but data reflects consensus industry estimates). [3] U.S. Food & Drug Administration (FDA) Orange Book and similar international patent databases. (Data regarding patent expiries are publicly accessible and have been cross-referenced).